Management is buying the same thing twice: proven demand from one place is being replicated into identified new places r
The model's full reasoning — Q4 2021 call → NOWe need answer only YES or NO. Need analyze transcript. Need determine if management describes currently in middle of copying a part of own business already working into additional places where same demand already visible. Need identify specific proven instance, copies being stood up now, demand at destination, scale. Transcript: Vanda Pharmaceuticals. Products HETLIOZ, Fanapt, tradipitant. Need see if any expansion of proven unit? Hmm. They discuss HETLIOZ for Non-24, SMS launch. "We launched HETLIOZ and HETLIOZ LQ for indication of night-time sleep disturbances in patients with Smith-Magenis Syndrome. More than 50 patients with SMS are currently on treatment and more are awaiting payer approval. We're working closely with advocacy organizations in direct-to-consumer campaigns to increase awareness around Smith-Magenis Syndrome. We recognize that many patients with SMS remain undiagnosed and are currently treated for various new developmental disorders. Through our genetics platform, we have recently discovered that up to 100,000 patients diagnosed with autism actually carry potential pathogenic mutations in the RAI1 gene which is often deleted or mutated in patients with SMS. We believe that this discovery will aid in the molecular identification of patients with SMS among the autism population of patients and offer them a new therapeutic solution. We look forward to beginning to resolve the access hurdles for sighted patients with Non-24, expanding our SMS population of treated patients and advancing HETLIOZ through the clinical program of delayed sleep-wake phase disorder." Is this copying a proven unit? HETLIOZ already approved for Non-24, now launched for SMS. SMS is new indication, not additional instances of same piece? It's same drug, new indication. Demand? More than 50 patients on treatment, more awaiting payer approval. But is it "currently in middle of copying a part of its own business that is already working into additional places where same demand is already visible"? Maybe not. It's expanding indication, not replicating a unit. Also "genetics platform" discovery of autism patients with RAI1 mutations, but not yet proven. No. Other possible: HETLIOZ payer access expansion to states? They mention 18 states with restrictions, 10 revised criteria, 4 discuss, 4 reviewing. This is not copying a business unit; it's regulatory/access.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| VSEC | VSE Corporation | Q3 2022 | 2022-10-28 | B+ |
| FSLR | First Solar, Inc. | Q3 2022 | 2022-10-28 | C+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| GDS | GDS Holdings Limited | Q2 2021 | 2021-08-17 | C+ |
| TPIC | TPI Composites, Inc. | Q3 2018 | 2018-11-11 | C |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| FOLD | Amicus Therapeutics, Inc. | Q1 2018 | 2018-05-08 | C+ |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| VSAT | Viasat, Inc. | Q4 2017 | 2017-05-23 | C+ |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
GDS · Q2 2021 → YESThe question is whether management describes the company as currently in the middle of copying a part of its own business that is already working into additional places where the same demand is alread...YES The transcript shows management describing a clear, present-tense replication of their proven China-based data center platform into new markets (Hong Kong, Macau, Southeast Asia) where demand is already visible and committed. William Huang explicitly references the “proven” China edge-of-town model (land-and-expand MOUs, 500 000 sqm secured pipeline, hyperscale orders already landed) and states they are “currently developing two purpose-built data centers” in Hong Kong (HK1/HK2) with most capacity “already allocated to strategic customers pending contracts,” plus a new building (HK4) under agreement and a heads-of-agreement for HK3, creating “nearly 80 megawatts of purpose-built capacity through to 2027.” For Macau they have a JV to acquire brownfield sites for redevelopment (20 MW).
FOLD · Q1 2018 → YESThe question is about whether management describes the company as currently copying a proven part of its business into additional places where demand is already visible. YES The transcript shows management describing Galafold as a proven commercial offering (Q1 revenue $16.7M, 300% YoY growth, hundreds of patients, high compliance, 7 approvals, 18 countries with pricing/reimbursement) that is now being replicated into additional markets.
TPIC · Q3 2018 → YESThe question is whether management describes the company as currently in the middle of copying a part of its own business that is already working into additional places where the same demand is alread...YES The transcript shows management describing a proven manufacturing operation (existing dedicated lines and plants in the U.S.